Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease

Inclusion Criteria: 1. 18-80 years of age, males or non-pregnant women; 2. Evidence of silent ischemia, stability or in patients with old myocardial infarction or unstable angina; 3. Primary target lesion, in situ coronary artery disease; 4. Target lesion length ≤ 60mm, target lesion diameter 2.75mm or 4.0mm (Visual method); 5. The target lesion diameter stenosis ≥ 70% (Visual method); 6. Each target lesion implantation the same stent (Firehawk stand); 7. With indications for coronary artery bypass surgery; 8. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up. Exclusion Criteria: 1. Within 72h of any acute myocardial infarction; 2. Unprotected left main coronary artery disease, triple vessel lesions which need treated all; 3. Severe calcified lesions that cannot be successfully expanded and distorting lesions not suitable for stent delivery; 4. Artery and/or vein bypass graft lesions; 5. Intracoronary implantation of any branding stents within 1 year; 6. Severe congestive heart failure (NYHA class III and above), or left ventricular ejection fraction \<35% (ultrasound or left ventricular angiography); 7. Preoperative renal function serum creatinine \>2.0mg/DL; 8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; 9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; 10. The patient's life expectancy is less than 12 months; 11. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; 12. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; 13. Heart transplantation patients.